A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.
Takuji OkusakaManabu MorimotoYuichiro EguchiShinichiro NakamuraShuichi IinoRie KageyamaPublished in: Drugs in R&D (2023)
ClinicalTrials.gov identifier NCT02358395, registered on 9 February 2015.